Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorQianfoshan Hospital
About this trial
To investigate the effect of different doses of flumazenil antagonism on remimazolam plasma concentration in patients undergoing renal transplantation under general anesthesia.
Eligibility criteria
Qualifiers
Age ≥ 18 years and < 65 years
Patients undergoing elective kidney transplant surgery
Signed the informed consent for the clinical study
Disqualifiers
Liver decompensation (Child B/C)
History of liver transplant
Previous allergies or other serious adverse reactions to narcotic drugs
Intraoperative depth monitoring of anesthesia is not expected
Trial design
Treatments tested in this trial
- Flumazenil Injection（F1 group）
- Flumazenil Injection（F2 group）
- Saline（C group）
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
This trial has no locations
Sponsors and collaborators
Qianfoshan Hospital
Lead sponsor
Source ClinicalTrials.gov